Verve Therapeutics Inc (NASDAQ: VERV) kicked off on Tuesday, up 0.40% from the previous trading day, before settling in for the closing price of $4.98. Over the past 52 weeks, VERV has traded in a range of $4.59-$21.04.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 126.44% over the last five years. While this was happening, its average annual earnings per share was recorded 15.18%. With a float of $63.94 million, this company’s outstanding shares have now reached $81.97 million.
The firm has a total of 255 workers. Let’s measure their productivity.
Verve Therapeutics Inc (VERV) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verve Therapeutics Inc is 23.85%, while institutional ownership is 81.68%. The most recent insider transaction that took place on May 14 ’24, was worth 475,760. In this transaction an insider of this company bought 76,000 shares at a rate of $6.26, taking the stock ownership to the 342,509 shares. Before that another transaction happened on Apr 02 ’24, when Company’s Chief Administrative Officer sold 1,514 for $8.24, making the entire transaction worth $12,475. This insider now owns 8,659 shares in total.
Verve Therapeutics Inc (VERV) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 15.18% per share during the next fiscal year.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Take a look at Verve Therapeutics Inc’s (VERV) current performance indicators. Last quarter, stock had a quick ratio of 19.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.88, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.92 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Analysing the last 5-days average volume posted by the [Verve Therapeutics Inc, VERV], we can find that recorded value of 1.57 million was better than the volume posted last year of 1.31 million. As of the previous 9 days, the stock’s Stochastic %D was 40.70%. Additionally, its Average True Range was 0.33.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 2.81%, which indicates a significant decrease from 34.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.48% in the past 14 days, which was lower than the 92.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.67, while its 200-day Moving Average is $10.67. Now, the first resistance to watch is $5.13. This is followed by the second major resistance level at $5.25. The third major resistance level sits at $5.42. If the price goes on to break the first support level at $4.84, it is likely to go to the next support level at $4.67. Should the price break the second support level, the third support level stands at $4.55.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
The company with the Market Capitalisation of 419.85 million has total of 83,965K Shares Outstanding. Its annual sales at the moment are 11,760 K in contrast with the sum of -200,070 K annual income. Company’s last quarter sales were recorded 5,700 K and last quarter income was -48,740 K.
